First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Expert opinion on drug safety（2023）
Abstract
Despite seemingly different nature and frequencies, ADRs are the second reason of treatment discontinuation for both bDMARDs. Furthermore, 2-, 5- and 10-year drug survival is longer for ETN compared to ADA.
MoreTranslated text
Key words
adverse drug reactions,bDMARDs,biologicals,drug survival,real-world data,rheumatoid arthritis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined